The next big advance in cancer treatment could be a vaccine

76

A potential breakthrough in cancer treatment lies in the development of vaccines.

Scientists believe that after years of limited success, research has now reached a crucial turning point, with many experts predicting the emergence of more vaccines within the next five years.

These vaccines are not your traditional disease-preventing shots; instead, they are designed to shrink tumors and prevent cancer from recurring. Promising targets for these experimental treatments include breast and lung cancer, with recent advancements reported in combating deadly skin cancer melanoma and pancreatic cancer.

Dr. James Gulley, a leading figure at the National Cancer Institute’s center for immune therapies and cancer treatment vaccines, expressed optimism, stating, “We’re making progress. Now we need to improve upon it.”

Researchers now have a deeper understanding of how cancer evades the body’s immune system. Cancer vaccines, like other immunotherapies, work by bolstering the immune system to detect and eliminate cancer cells. Some of the latest vaccines employ mRNA technology, originally developed for cancer research but first utilized in COVID-19 vaccines.

For a vaccine to be effective, it must train the body’s T cells to identify cancer as a threat, explains Dr. Nora Disis from UW Medicine’s Cancer Vaccine Institute in Seattle. Once educated, these T cells can travel throughout the body to locate and neutralize cancerous cells. Dr. Disis vividly describes the T cells as having “feet,” envisioning them crawling through blood vessels to reach tissues.

Patient volunteers play a crucial role in this research. One such volunteer, Kathleen Jade, opted to participate in an experimental vaccine trial after being diagnosed with breast cancer just before embarking on a global adventure with her husband. She believes that even a slim chance of success makes the trial worthwhile, alongside her ongoing standard treatment.

Developing effective treatment vaccines has proven challenging. The first treatment vaccine, Provenge, gained approval in the U.S. in 2010 for the treatment of advanced prostate cancer. It involves processing a patient’s immune cells in a laboratory and reintroducing them intravenously. Other treatment vaccines are available for early-stage bladder cancer and advanced melanoma.

Initial research on cancer vaccines faced setbacks as cancer proved adept at outsmarting patients’ weakened immune systems, as explained by Olja Finn, a vaccine researcher at the University of Pittsburgh School of Medicine. Consequently, researchers have shifted their focus to patients with earlier-stage diseases, as the experimental vaccines did not yield significant benefits for advanced-stage patients. One upcoming study aims to examine the potential of a vaccine in women with low-risk, noninvasive breast cancer called ductal carcinoma in situ.

Furthermore, the prevention of cancer through vaccines is also an area of progress. Decades-old hepatitis B vaccines have been successful in preventing liver cancer, while HPV vaccines introduced in 2006 have been effective in preventing cervical cancer.

Dr. Susan Domchek, director of the Basser Center at Penn Medicine in Philadelphia, is currently recruiting healthy individuals with BRCA mutations for a vaccine trial. These mutations increase the risk of breast and ovarian cancer, and the goal is to eliminate abnormal cells at an early stage before they cause harm. Dr. Domchek likens the process to periodically weeding a garden or erasing a whiteboard.

Other researchers are working on vaccines to prevent cancer in individuals with precancerous lung nodules and those with inherited conditions that elevate their cancer risk.

Dr. Steve Lipkin, a medical geneticist at New York’s Weill Cornell Medicine, leading an effort funded by the National Cancer Institute, asserts that “vaccines are probably the next big thing” in the battle against cancer. Researchers like him are dedicated to this pursuit.

Recruiting patients for cancer vaccine trials has been remarkably straightforward for those with the inherited condition Lynch syndrome, which carries a lifetime cancer risk of 60% to 80%, according to Dr. Eduardo Vilar-Sanchez of MD Anderson Cancer Center in Houston. Dr. Vilar-Sanchez is leading two government-funded studies on vaccines for Lynch-related cancers.

Pharmaceutical companies Moderna and Merck are collaborating on the development of a personalized mRNA vaccine for melanoma patients, with a large-scale study set to commence this year. These vaccines are customized for each patient based on the specific mutations found in their cancer tissue. Personalized vaccines of this nature can train the immune system to target the unique mutation fingerprint of the cancer and destroy those cells. However, these vaccines are expected to be expensive, as each vaccine has to be tailored from scratch. Dr. Patrick Ott of Dana-Farber Cancer Institute in Boston compares the cost to that of COVID-19 vaccines, which could be produced more affordably if they were not personalized.

At UW Medicine, vaccines are being developed to benefit a broader range of patients rather than a single individual. Clinical trials are currently underway for both early-stage and advanced breast, lung, and ovarian cancers. Some preliminary results may be available as early as next year.

Todd Pieper, a 56-year-old from suburban Seattle, is participating in a vaccine trial aimed at shrinking lung cancer tumors. Despite his cancer having spread to his brain, he remains hopeful that he will live long enough to witness his daughter’s graduation from nursing school next year. He says he has nothing to lose and everything to gain, not only for himself but also for future patients.

Jamie Crase, who was diagnosed with advanced ovarian cancer at the age of 34, was one of the first individuals to receive the ovarian cancer vaccine in a safety study eleven years ago. She believed she would not live long, even drafting a will and bequeathing her favorite necklace to her best friend. Now at the age of 50, she is cancer-free and still wears the necklace. While she cannot be certain if the vaccine played a role in her recovery, she is grateful to be alive.

In conclusion, the field of cancer treatment is on the brink of a significant breakthrough with the development of vaccines. Ongoing research and clinical trials offer hope for more effective treatments, including vaccines that can shrink tumors and prevent cancer recurrence. While challenges remain, scientists are dedicated to advancing this field and reducing cancer-related deaths. Patient volunteers are crucial to the success of these endeavors, and early results indicate promising outcomes in various types of cancer. Vaccines may not only be used for treatment but also for the prevention of cancer in individuals at high risk. Collaboration between researchers, pharmaceutical companies, and medical institutions is driving this progress, with the aim of providing personalized and more accessible vaccines in the future.

Frequently Asked Questions (FAQs) about cancer treatment vaccines

More about cancer treatment vaccines

• Advances in Cancer Treatment Vaccines
• Immunotherapy for Cancer Treatment
• Cancer Treatment Vaccines: Current Perspectives
• mRNA Technology in Cancer Vaccines
• Cancer Prevention Vaccines
• Progress in Cancer Vaccine Research
• Clinical Trials for Cancer Treatment Vaccines